RxDoctor Payments Data

Muhammad Ebad Rehman, MD

Internal Medicine · Bowling Green, KYNPI 1538654876

Payments from drug & device makers

$1,662in general payments, 2019–2025

Across 71 payments — averaging $23.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$319
  • Bayer$199
  • Travere Therapeutics, Inc.$184
  • Calliditas Therapeutics US Inc.$180
  • Otsuka America Pharmaceutical, Inc.$180
  • Ardelyx, Inc.$146
  • plus $453 from 9 others

What the payments were for

  • Food & beverage$1,64299%
  • Education$211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,662 in reported general payments places this provider in the 70th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$180,567
Medicare patients
419
Services billed
1,460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XphozahTenapanor Hcl51$150,887
AuryxiaFerric Citrate26$61,318
FarxigaDapagliflozin Propanediol63$55,610
JardianceEmpagliflozin56$47,540
VeltassaPatiromer Calcium Sorbitex23$38,246
KerendiaFinerenone13$16,011
LokelmaSodium Zirconium Cyclosilicate19$15,153
ProsolParenteral Amino Acid 20% No.154$12,012
Sevelamer Carbonate62$7,881
Midodrine Hcl19$3,624
Bumetanide32$2,079
Furosemide195$1,058
Nifedipine ErNifedipine27$871
Potassium Chloride56$598
Lisinopril149$595

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$319$70,76382 claims
Boehringer IngelheimJardiance$15$47,54056 claims
BayerKerendia$199$16,01113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Bowling Green

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →